A four-year collaboration to identify novel drug targets, tackle new subsets of disease and enable rapid progression of clinical programmes has been signed between GSK and 23andMe, a leading consumer genetics company with more than 5 million customers and a portfolio of early stage therapeutic research programmes across a wide range of disease indications. Both companies shall bring existing early stage programmes within the collaboration; GSK will contribute its LRRK2 inhibitor, which is currently in preclinical development as a potential treatment for Parkinson’s disease. All activities will initially be co-funded (50%/50%). GSK has also made a $300 million equity investment in 23andMe, and it will have the right to analyse its database for validation of GSK’s existing therapeutic portfolio as well as leverage 23andMe’s capabilities for clinical trial recruitment. 23andMe customers voluntary and affirmatively consented to participate to research and mantain the control of their data, which are used after de-identification, so no individual will be identifiable to GSK.